Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors

Cancer Discovery

Volumn 4, Issue 7, 2014, Pages 773-780

  Levy, Jean M Mulcahy ^a   Thompson, Joshua C ^a   Griesinger, Andrea M ^a   Amani, Vladimir ^a   Donson, Andrew M ^a   Birks, Diane K ^b   Morgan, Michael J ^b   Mirsky, David M ^b   Handler, Michael H ^b   Foreman, Nicholas K ^a   Thorburn, Andrew ^b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHLOROQUINE; LACTATE DEHYDROGENASE; SHORT HAIRPIN RNA; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; AUTOPHAGY; BRAIN TUMOR; CANCER CELL CULTURE; CANCER THERAPY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROSCOPY; MTT ASSAY; QUANTITATIVE ANALYSIS; SAMPLING; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TUMOR GROWTH; WESTERN BLOTTING; BRAIN NEOPLASMS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHILD; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHILD; CHLOROQUINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84904048411     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0049     Document Type: Article

References (26)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. M utations of the BRAF gene in human cancer. N ature 2002; 417: 949-54.
2. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 2011; 17: 7595-604.
3. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE 2011; 6: e17948.
4. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010; 12: 621-30.
5. Kleinschmidt-DeMasters BK, Birks DK, Aisner DL, Hankinson TC, Rosenblum MK. Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization. Am J Surg Pathol 2011; 35: 1894-901.
6. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011; 121: 397-405.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
8. Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012; 7: e23-4.
9. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038-40.
10. O'Donnell E, Raje NS. Targeting BRAF in multiple myeloma. Cancer Discov 2013; 3: 840-2.
11. Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 2013; 31: e159-60.
12. Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ, Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol 2010; 130: 1657-67.
13. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013; 3: 1272-85.
14. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011; 17: 3478-89.
15. Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther 2011; 131: 130-41.
16. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.
17. Levy JM, Thorburn A. Modulation of pediatric brain tumor autophagy and chemosensitivity. J Neurooncol 2012; 106: 281-90.
18. Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 429-33.
19. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767-74.
20. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007; 67: 388-91.
21. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337-43.
22. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-66.
23. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014; 124: 1406-17.
24. Pacific Pediatric Neuro-Oncology Consortium [Internet]. Safety and Phase 0 Study of vemurafenib, and oral inhibitor of BRAFV600E in Children with Recurrent/Refractory BRAFV600E-mutant gliomas. [cited 2013 Dec 1]. Available from: http://www.pnoc.us/clinical-trials/ safety-and-phase-0-study-vemurafenib-oral-inhibitor-brafv600echildren.
25. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, et al. Vemurafenib in pediatric patients with BRAFV600E mutated highgrade gliomas. Pediatr Blood Cancer 2014; 61: 1101-3.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.